Company profile
Equillium, Inc.
NASDAQ: EQ · Healthcare · Biotechnology
PublicHQ La Jolla, CACIK 0001746466Reports USD
#462 of 1,418 Healthcare companies by revenue60th-percentile growth
EA Score
44DFH 56DQ 27GM —SS 45
v0.1 · 55/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ disclosure history, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$22.4M
Employees
14
as of 2026-08-18
Market cap
$148.9M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$41.1M$41.1M2024
Net income-$22.4M-$22.4M2025
Operating income-$23.6M-$23.6M2025
Total assets$31.9M$31.9M2025
Liabilities$3.3M$3.3M2025
Equity$28.6M$28.6M2025
Revenue trend
FY2022 – FY2024 · USD
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Equillium, Inc.’s revenue?
Equillium, Inc. booked $41.1M in FY2024 revenue, growing 14% year over year — faster than most Healthcare companies we track, at a -54.5% net margin.
Peers · Healthcare
Selectis Health, Inc.60CKORU Medical Systems, Inc.72BFilana Therapeutics, Inc.42DMyomo, Inc.53DEditas Medicine, Inc.45DAlpha Teknova, Inc.58CKey facts
CEOBruce D. Steel
SectorHealthcare
IndustryBiotechnology
HeadquartersLa Jolla, CA
ExchangeNASDAQ: EQ
Employees14
IPO date2018-10-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.